Brookline Capital Markets analyst Kumaraguru Raja maintained a Buy rating on Oncternal Therapeutics (ONCT - Research Report) yesterday and set a price target of $12.00. The company's shares closed yesterday at $1.11.According to TipRanks, Raja is a 2-star analyst with an average return of 0.5% and a 34.30% success rate. Raja covers the Healthcare sector, focusing on stocks such as Veru, 9 Meters Biopharma, and Daré Bioscience.Oncternal Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $10.00.See the top stocks recommended by analysts >>The company has a one-year high of $4.63 and a one-year low of $0.69.
https://www.tipranks.com/news/blurbs/brookline-capital-markets-sticks-to-their-buy-rating-for-oncternal-therapeutics-onct?utm_source=advfn.com&utm_medium=referral
Oncternal Therapeutics (NASDAQ:ONCT)
Gráfico Histórico do Ativo
De Ago 2022 até Set 2022 Click aqui para mais gráficos Oncternal Therapeutics.
Oncternal Therapeutics (NASDAQ:ONCT)
Gráfico Histórico do Ativo
De Set 2021 até Set 2022 Click aqui para mais gráficos Oncternal Therapeutics.